ANALYSIS — Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug

European Commission review to follow after EMA panel backing RevMed gears up hiring in Europe, LinkedIn postings show Analysts say company can pursue ex-US launch alone By Sriparna Roy and Bhanvi Satija Oct 15 (Reuters) — Revolution Medicines is laying the groundwork for a broad European commercial rollout of its pancreatic cancer drug, signaling confidence in its ability to bring the therapy to market without relying on a local partner to help sell it. Following impressive clinical data against the notoriously difficult-to-treat cancer, analysts forecast peak annual global sales of $11.5 billion for Revolution's Rasonque, which won speedy US approval in August after an FDA expedited review. The European Medicines Agency's human medicines committee on Thursday recommended a marketing authorization for the oral drug, known chemically as daraxonrasib. It will now be reviewed by the European Commission. Small biotechs such as Revolution Medicines typically strike regional licensing deals in markets where they lack the scale or expertise to negotiate with government health systems, and in some cases ultimately sell themselves to larger drugmakers. "We are doing everything that we can p